Issued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)Three drugs in human trials. A platform licensed from one of the world's top cancer-research universities. A market cap smaller than a Manhattan apartment. For investors willing to look where almost no one is looking, GT Biopharma is the kind of asymmetric setup that biotech is built on.NEW YORK, May 29, 2026 /CNW/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ:GTBP) carried a market capitalization of roughly $13 million. Thirteen million. That is not a typo, and it is not a shell company. It is a clinical-stage immuno-oncology company with three sep

SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that Artiva management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026, at 9:20 am EDT. To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva's website. The archived audio webcast will remain available for replay on Artiva's website for 90 days. About Arti

Late-breaking oral presentation to highlight AlloNK + rituximab clinical responses comparable to autologous CAR T-cell therapy in 31 patients with rheumatologic diseases, including 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up with no patients relapsing or requiring new immunomodulatory agentsOral presentation to feature positive experience in the first patient with severe Sjögren disease treated with AlloNK + rituximabPoster presentations to highlight deep, consistent B-cell depletion comparable to CD19 CAR T-cell therapies and a favorable safety profile in immune-mediated diseasesLive post-meeting webcast to be held Monday, June 8

Veteran biotechnology executive with more than 20 years of leadership experience spanning research, clinical development, commercialization and company building Proven track record advancing multiple therapeutics from discovery through FDA approval and commercialization, including PREZISTA® and INTELENCE® SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced the appointment of Diego Miralles, M.D., as President and Head of Research and Development. Dr. Miralles brings

Market News Updates News Commentary Breakthrough immunotherapies, ADCs, and precision oncology platforms continue driving major investor attention across the global cancer treatment sectorNEW YORK, May 14, 2026 /CNW/ -- Momentum around solid tumor cancer treatments is picking up fast as new technologies and therapies continue delivering encouraging results across some of the hardest-to-treat cancers. From lung and breast cancer to colorectal, ovarian, and pancreatic cancers, drug developers are making real progress with next-generation immunotherapies, targeted treatments, and antibody-drug conjugates (ADCs). What's getting the industry excited is that many of these newer therapies are showi

SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced the pricing of an underwritten offering of 23,871,526 shares of its common stock at a price of $11.52 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 2,170,138 shares of common stock at a purchase price of $11.5199 per share, which equals the offering price per share of the common stock less the $0.0001 exercise price per share of each pre-funded warrant. All the

Initial AlloNK® (AB-101) clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no patients relapsing or requiring new immunomodulatory agents AlloNK treatment regimen demonstrated a consistent pattern of deep B-cell depletion and tolerability results supportive of outpatient administration in community rheumatology settings U.S. Food and Drug Administration (FDA) alignment on a single Phase 3 registrational randomized controlled trial evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 refractory RA patients, with ACR50 at six

Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no patients relapsing or requiring new immunomodulatory agents AlloNK treatment regimen demonstrated tolerability results supportive of outpatient administration in community rheumatology settings, with no CRS, ICANS, or treatment discontinuations observed in autoimmune patients treated with AlloNK More than 70 autoimmune patients treated with AlloNK across more than 40 active clinical sites, mostly in community settings, providing a strong foundation for planned registrational trial initiation in H

SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that Artiva management will participate in a panel as well as a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 2:15 p.m. EDT. To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva's website. The archived audio webcast will remain available for replay on Artiva's w

Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026 U.S. Food and Drug Administration (FDA) interaction to discuss potential pivotal trial design for AlloNK expected in first half of 2026 Strengthened board and executive leadership with deep immunology, commercial and financial expertise Robust balance sheet with cash, cash equivalents and investments of $108.0 million as of December 31, 2025, expected to fund operations into Q2 2027 SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessib

H.C. Wainwright resumed coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $12.00

H.C. Wainwright initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $20.00

Jefferies initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $21.00

Cantor Fitzgerald initiated coverage of Artiva Biotherapeutics with a rating of Overweight and set a new price target of $23.00

TD Cowen initiated coverage of Artiva Biotherapeutics with a rating of Buy

Wedbush initiated coverage of Artiva Biotherapeutics with a rating of Outperform and set a new price target of $18.00

Needham initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $23.00

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

3 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

144 - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

144 - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

SCHEDULE 13G - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

SCHEDULE 13D/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

424B5 - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

FWP - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

10-Q - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

SC 13G/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

SC 13D/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

SC 13G - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

SC 13G - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

SC 13G - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

SC 13D - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

SC 13D - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

Veteran biotechnology executive with more than 20 years of leadership experience spanning research, clinical development, commercialization and company building Proven track record advancing multiple therapeutics from discovery through FDA approval and commercialization, including PREZISTA® and INTELENCE® SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced the appointment of Diego Miralles, M.D., as President and Head of Research and Development. Dr. Miralles brings

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Thad Huston as Chief Financial Officer. Mr. Huston brings proven expertise in capital allocation, operational execution and global commercialization to support Artiva as it advances AlloNK in autoimmune diseases and continues building an organization positioned for long-term value creation. "We are delighted to welcome Thad to Artiva as he brings strong late-stage development and comme

SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Elaine Sorg to its Board of Directors. Ms. Sorg brings more than 35 years of executive leadership and commercial experience in the biopharmaceutical industry to Artiva, including leading the commercialization of major immunology therapies such as HUMIRA® (adalimumab) and RINVOQ® (upadacitinib) for rheumatoid arthritis. "We are thrilled to welcome Elaine to Artiva's board at such an imp

– 25+ years of biotherapeutics leadership, including serving as founding CEO of two NASDAQ-listed companies and securing over $500 million in funding – Expertise in advanced therapeutics development, driving multiple cell and gene therapy product candidates from discovery through to clinical trials     COVENTRY, England, Jan. 8, 2026 /PRNewswire/ -- NanoSyrinx, a synthetic biology company developing Nanosyringes™ as a novel platform for targeted intracellular delivery of biologic therapeutics, today announced the appointment of Thomas J. Farrell as Chief Executive Officer and Director. Tom succeeds company founder Joe Healey, who will remain involved in the company, ensuring continuity and o

IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis First trial to explore an allogeneic cell therapy in refractory rheumatoid arthritis and Sjögren's disease in the U.S. Initial safety, translational data, and lead indication selection to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026 Longer-term clinical data from Phase 1/2 trial exploring AlloNK + rituximab in B-NHL in heavily pretreated CAR-T naïve patients to be presented at ASGCT, demonstrating complete response rates and

SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Subhashis Banerjee, M.D., as Chief Medical Officer. Dr. Banerjee is a trained rheumatologist and immunologist who brings over two decades of clinical development experience in autoimmune diseases, most recently as Disease Area Head for Rheumatology and Dermatology Global Development at Bristol Myers Squibb (BMS), and Senior Vice President (SVP), Clinical Development at VYNE Therapeutics, Inc.

SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Dan Baker, M.D., as an independent member of its Board of Directors. Dr. Baker brings over two decades of drug development experience in the pharmaceutical industry. He is currently the interim Chief Development Officer of Cue Biopharma, Inc., and previously held a 19-year tenure at Johnson & Johnson (Janssen/Centocor) (J & J) most recently as the Vice President of Immunology R&D. "Dan is a ph

SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. (NASDAQ:CDXS), a leading enzyme engineering company, and was the former CTO of Allog